| |
All patients (n = 1252)
|
AKI (n = 285)
|
No AKI (n = 967)
|
|---|
|
Age, year a
|
58.0 (49.0–67.8)
|
65.0 (54.0–71.0)
|
57.0 (48.0–66.0)
|
|
Male sexa
|
685 (54.7%)
|
176 (61.8%)
|
509 (52.6%)
|
|
Hypertension a
|
321 (25.6%)
|
112 (39.3%)
|
209 (21.6%)
|
|
Diabetes a
|
286 (22.8%)
|
108 (37.9%)
|
178 (18.4%)
|
|
Alcohol > 40 g/day
|
244 (19.5%)
|
65 (22.8%)
|
179 (18.5%)
|
|
Diagnosis at entry a
|
|
CH
|
1008 (80.5%)
|
186 (18.5%)
|
822 (81.5%)
|
|
Com-LC
|
123 (9.8%)
|
34 (27.6%)
|
89 (72.4%)
|
|
Decom-LC or HCC
|
121 (9.7%)
|
65 (53.7%)
|
56 (46.3%)
|
|
Genotype
|
|
1
|
545 (43.5%)
|
108 (37.9%)
|
437 (45.2%)
|
|
2
|
603 (48.2%)
|
150 (52.6%)
|
453 (46.8%)
|
|
3
|
101 (8.1%)
|
26 (9.1%)
|
75 (7.8%)
|
|
Others
|
3 (0.2%)
|
1 (0.4%)
|
2 (0.2%)
|
|
Extrahepatic malignancy a
|
90 (7.2%)
|
35 (12.3%)
|
55 (5.7%)
|
|
SVR a
|
606 (48.4%)
|
49 (17.2%)
|
557 (57.7%)
|
|
HCV RNA > 600,000 IU/mL
|
202 (16.1%)
|
42 (14.7%)
|
160 (16.5%)
|
|
Albumin, g/dL a
|
4.1 (3.7–4.4)
|
3.7 (3.1–4.1)
|
4.2 (3.9–4.5)
|
|
Bilirubin, mg/dL a
|
0.69 (0.50–1.00)
|
0.77 (0.50–1.25)
|
0.67 (0.50–0.94)
|
|
Platelet, ×109/L a
|
183.0 (131.0–232.0)
|
151.0 (102.0–215.0)
|
190.0 (142.0–233.0)
|
|
PT-INR a
|
1.03 (0.99–1.11)
|
1.09 (1.02–1.22)
|
1.01 (0.98–1.09)
|
|
Child-Pugh B or C at entry a
|
112 (8.9%)
|
66 (58.9%)
|
46 (41.1%)
|
|
MELD score at entry a
|
7.0 (6.0–8.0)
|
8.0 (7.0–10.0)
|
7.0 (6.0–8.0)
|
|
Follow-up period (year)
|
4.2 (2.1–7.9)
|
4.6 (2.1–8.0)
|
4.1 (2.0–7.8)
|
- Data are presented as median (interquartile range) for continuous data and percentages for categorical data
- Abbreviations: CH Chronic hepatitis, Com-LC Compensated cirrhosis, Decom-LC Decompensated cirrhosis, HCC Hepatocellular carcinoma, SVR Sustained virologic response, HCV Hepatitis C virus, PT-INR Prothrombin time-international normalized ratio, MELD score Model For End-Stage Liver Disease score
- a p < 0.05 AKI vs No AKI using the Mann-Whitney U test and Chi-squared test
